Previous 10 |
home / stock / bti:cc / bti:cc news
NEW HAVEN, Conn., Dec. 14, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI) (OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal ...
/C O R R E C T I O N -- Investment Industry Regulatory Organization of Canada (IIROC) - Resumptions Canada NewsWire In the news release, IIROC Trading Resumption - BTI, issued 13-Dec-2022 by Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumption...
NEW HAVEN, Conn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI) (the “ Company ” or “ Bioasis ”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epi...
NEW HAVEN, Conn., Oct. 28, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on e...
NEW HAVEN, Conn., July 29, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB 3™ platform technology for the delivery of therapeutics a...
Phase 2 ready assets transform Bioasis into a clinical stage company with a multi-asset pipeline focused on rare and orphan drug indications Unique approach to neurodegeneration targeting remyelination Initial indications Chronic Inflammatory Degenerative Polyneuropathy, G...
NEW HAVEN, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therap...
NEW HAVEN, CONN., U.S.A., May 10, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”) a biopharmaceutical company developing its proprietary xB 3TM platform technology for the delivery of therapeutics a...
NEW HAVEN, CONN., U.S.A., April 11, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”), a biopharmaceutical company developing its proprietary xB 3TM platform technology for the delivery of therapeutics...
News, Short Squeeze, Breakout and More Instantly...
Bioasis Technologies Inc. Company Name:
BTI:CC Stock Symbol:
TSXVC Market:
Bioasis Technologies Inc. Website:
Canadian Investment Regulatory Organization Trading Halt - BTI Canada NewsWire VANCOUVER, BC , March 21, 2024 /CNW/ - The following issues have been halted by CIRO Company: Bioasis Technologies Inc. TSX-Venture Symbol: BTI All Issues: Yes Reason: Ceas...
A look at the top 10 most actives in Canada Athabasca Oil Corporation (ATH) rose 1.8% to $5.01 on volume of 15,351,812 shares Baytex Energy Corp. (BTE) rose 0.2% to $4.41 on volume of 15,326,322 shares Cenovus Energy Inc. (CVE) rose 1.9% to $24.09 on volume of 13,245,579 shares BMO Equa...
Canadian Utilities Limited Class A Non-Voting Shares (CU:CA) is expected to report $0.69 for Q4 2023 Artis Real Estate Investment Trust (AX.UN:CA) is expected to report for Q4 2023 Pinetree Capital Ltd. (PNP:CA) is expected to report for Q4 2023 Sego Resources Inc. (SGZ:CA) is expecte...